Last reviewed · How we verify

norelgestromin + ethinyl estradiol; mercilon — Competitive Intelligence Brief

norelgestromin + ethinyl estradiol; mercilon (norelgestromin + ethinyl estradiol; mercilon) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: contraceptive. Area: Women's Health.

phase 3 contraceptive Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

norelgestromin + ethinyl estradiol; mercilon (norelgestromin + ethinyl estradiol; mercilon) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Norelgestromin and ethinyl estradiol are used to prevent pregnancy by suppressing ovulation and altering cervical mucus and the uterine lining.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
norelgestromin + ethinyl estradiol; mercilon TARGET norelgestromin + ethinyl estradiol; mercilon Johnson & Johnson Pharmaceutical Research & Development, L.L.C. phase 3 contraceptive
Ethinyl Estradiol / Norgestimate Oral Tablet Ethinyl Estradiol / Norgestimate Oral Tablet University of Colorado, Denver marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor
desogestrel/ethinyl estradiol desogestrel/ethinyl estradiol Teva Branded Pharmaceutical Products R&D, Inc. marketed Combined oral contraceptive Progesterone receptor, estrogen receptor
Depo Provera Depo Provera University of Alabama at Birmingham marketed Progestin; long-acting reversible contraceptive Progesterone receptor
Estradiol+Drospirenone Estradiol+Drospirenone Brigham and Women's Hospital marketed Combined oral contraceptive Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism
Ethinyl estradiol / dienogest Ethinyl estradiol / dienogest Helsinki University Central Hospital marketed Combined oral contraceptive Estrogen receptor, progesterone receptor
etonogestrel-releasing implant contraceptive etonogestrel-releasing implant contraceptive University of Sao Paulo marketed Progestin contraceptive Progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (contraceptive class)

  1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
  2. Ospedale Policlinico San Martino · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). norelgestromin + ethinyl estradiol; mercilon — Competitive Intelligence Brief. https://druglandscape.com/ci/norelgestromin-ethinyl-estradiol-mercilon. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: